Who
David Joseph Gaffin
EVP, CLO, Alkermes, Inc.
Company insider
Files Form 4 as: EVP, CLO, Alkermes, Inc., Alkermes.
In numbers
- Trades disclosed
- 255
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $2.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 28 May 2016
- Last trade
- 2 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 2 Oct 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $83K2,034 at $41.03 | filing |
| 3 Sep 2026filed 3 Sep 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $98K2,034 at $48.01 | filing |
| 3 Sep 2026filed 3 Sep 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $98K2,034 at $48.01 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $99K2,034 at $48.58 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $99K2,034 at $48.58 | filing |
| 6 Jul 2026filed 6 Jul 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $110K2,034 at $54.03 | filing |
| 6 Jul 2026filed 6 Jul 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $110K2,034 at $54.03 | filing |
| 4 Jun 2026filed 4 Jun 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $88K2,034 at $43.05 | filing |
| 4 Jun 2026filed 4 Jun 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $88K2,034 at $43.05 | filing |
| 4 May 2026filed 4 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $68K2,034 at $33.20 | filing |
| 4 May 2026filed 4 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $68K2,034 at $33.20 | filing |
| 6 Apr 2026filed 6 Apr 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $70K2,034 at $34.57 | filing |
| 6 Apr 2026filed 6 Apr 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $70K2,034 at $34.57 | filing |
| 3 Mar 2026filed 4 Mar 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $61K2,034 at $29.76 | filing |
| 3 Mar 2026filed 4 Mar 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $61K2,034 at $29.76 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $60K2,034 at $29.29 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —78,292 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —78,292 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —36,364 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —36,364 at $0.00 | filing |
News
Financial Survey: INmune Bio (NASDAQ:INMB) vs. Alkermes (NASDAQ:ALKS)ALKS · themarketsdaily.com · 20 Oct 2026Traders Buy High Volume of Put Options on Alkermes (NASDAQ:ALKS)ALKS · tickerreport.com · 17 Oct 2026Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)ALKS · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name David Joseph Gaffin; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.